N/A
N=14
4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation
Pancreatic Adenocarcinoma
Bottom Line
View on ClinicalTrials.gov: NCT01764659 ↗Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcome: Primary: Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation — 4.1; 2.5; 3.6; 3.9 units on a scale
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Contrast-enhanced 4D computed tomography (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Maryland, Baltimore
- Primary completion
- Oct 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation |
1.4; 0.6; 0.8 | — |
Summary
The primary objective is to study the feasibility and efficacy of individually optimized CE 4D-CT for PDA in radiotherapy simulation.
Eligibility Criteria
Inclusion Criteria
- Patients 18 years old or older
- Patients with PDA who have not had surgical removal of their tumor and who are planned for treatment with radiotherapy in the Radiation Oncology Department at the University of Maryland.
- Patients who have signed the contrast consent form and have been recommended by physicians to have contrast-enhanced CT scans.
- Patients who have signed the consent form for this study
Exclusion Criteria
- Pregnant or breast-feeding women.
- Patients with severely decreased renal function19-21.
- Patients with known severe allergic reactions to contrast.
- Patients who have difficulty lying flat on their back for extended periods of time.
- Patients with breaths per minute (BPM) rate less than 10, due to the limitation of 4D-CT image reconstruction software.
Data sourced from ClinicalTrials.gov (NCT01764659). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.